Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

CRISPR (NASDAQ:CRSP) develops gene-based medicines using its CRISPR/Cas9 platform, with therapies targeting diseases like ...

The second person ever has received a transplant with a genetically modified pig kidney.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

The team developed their CF rabbit model using CRISPR/Cas9 gene-editing technology ... paralleling early signs of diabetes progression in humans. Interestingly, female CF rabbits were more ...

Liposuction and plastic surgery aren't often mentioned in the same breath as cancer. But they are the inspiration for a new approach to treating cancer that uses engineered fat cells to deprive tumors ...

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

CRISPR Therapeutics is developing CTX112 for ... including the clinical trial for CTX211™ in Type 1 diabetes (T1D) and subsequent next generation programs. These programs focus on allogeneic ...